Gyroscope Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Gyroscope Therapeutics, a UK-based clinical-stage gene therapy company founded by Syncona, developed one-time gene therapies for eye diseases that cause blindness. Its lead candidate GT005, an AAV2-based therapy delivered under the retina, targeted geographic atrophy, an advanced form of dry age-related macular degeneration. In December 2021 Novartis agreed to acquire the company for up to $1.5 billion, including $800 million upfront and up to $700 million in milestones.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Product launch
Gyroscope merges with Orbit Biomedical to become an end-to-end ocular gene therapy company with its own retinal delivery capability.
- Acquisition
On December 22, 2021, Novartis agrees to acquire Gyroscope Therapeutics for up to $1.5 billion, with $800 million upfront and up to $700 million in milestones for GT005.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.